Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Cloudflare Inc (NET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Cloudflare Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Cloudflare Inc trades at $267.83 (market cap $95.27B). The key difference: Cloudflare Inc is far larger — about 2.4× Alnylam Pharmaceuticals, Inc.'s market cap, and Cloudflare Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | NET | |
|---|---|---|
Market Cap | $39.89B | $95.27B |
Sector | Health | Technology |
52-Week High | $491.22 | $275.58 |
52-Week Low | $278.09 | $160.16 |
Enterprise Value | $38.15B | $94.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Cloudflare (NET) trades at $268.40, down 2.61% over 24 hours but remains near recent highs. The stock shows strong technical momentum with bullish moving averages and recent analyst upgrades. Fundamentally, revenue grew to $2.17 billion in 2025, though net income remains negative at -$102 million. Recent news highlights Cloudflare's strategic pivot toward AI infrastructure, including a research pilot with OpenAI announced July 8, 2026.
Outlook remains optimistic due to AI-driven growth potential and consistent earnings beats, but high valuation multiples (P/S 40.36) and negative profitability pose risks. Analyst consensus is strongly bullish with a $250.33 price target, though competition and execution challenges could pressure shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Cloudflare Inc
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →
